Clinical Trial Update: Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PTX-022 (QTORIN, sirolimus) for safety and efficacy in microcystic lymphatic malformations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microcystic Lymphatic Malformation

Drugs mentioned

• PTX-022 (QTORIN Sirolimus) (sirolimus)

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: Microcystic Lymphatic Malformation | Phase 2 | Status: COMPLETED | Results posted: 2025-01-17